Merck is reorganizing its pharmaceutical operations to separate oncology treatments from its broader drug portfolio. This strategic reshuffle comes as the company prepares for the 2028 US patent expiry of Keytruda, its blockbuster cancer immunotherapy drug that has generated billions in annual revenue. The restructuring aims to optimize the company's focus as it faces the loss of exclusivity on its most profitable product.

Keytruda has been a cornerstone of Merck's growth strategy, with sales exceeding $20 billion annually in recent years. The drug's patent expiration represents a significant challenge for the pharmaceutical giant, which must now prepare for increased competition from biosimilars. Industry analysts suggest the split could help Merck better manage the transition and potentially accelerate development of new oncology treatments.

The move reflects a broader trend among pharmaceutical companies facing patent cliffs on major revenue generators. By separating its oncology division, Merck may be positioning itself to more effectively compete in the rapidly evolving cancer treatment market while protecting its other therapeutic areas from potential revenue declines.